Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 11/20 | 0.54 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GPR183 | P32249 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059849 | 0.89 | REV1 (0.74) | REV1L3MBTL1CHRNA7ABCB1ABCC1 | |
| SCHEMBL3045901 | 0.89 | REV1 (0.68) | REV1L3MBTL1CHRNA7ABCB1ABCC1 | |
| SCHEMBL3055739 | 0.87 | REV1 (0.72) | REV1L3MBTL1CHRNA7ABCB1ABCC1 | |
| SCHEMBL3041926 | 0.86 | DHCR7 (0.65) | ABCB1KDM4ETDP1 | |
| SCHEMBL3055433 | 0.86 | REV1 (0.70) | REV1L3MBTL1CHRNA7ABCB1ABCC1 | |
| SCHEMBL3046416 | 0.85 | REV1 (0.71) | REV1CHRNA7ABCB1ABCC1KDM4E | |
| SCHEMBL3050371 | 0.85 | REV1 (0.84) | REV1CHRNA7ABCB1ABCC1KDM4E | |
| SCHEMBL3061717 | 0.84 | ABCB1 (0.64) | REV1L3MBTL1CHRNA7ABCB1ABCC1 | |
| SCHEMBL3052241 | 0.84 | REV1 (0.76) | REV1L3MBTL1CHRNA7ABCB1ABCC1 | |
| SCHEMBL3052095 | 0.83 | KDM4E (0.50) | REV1ABCB1ABCC1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | claimed |
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| EP-2155192-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | Sterix Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008117061-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | STERIX LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222299-A1 | COMPOUND | MKI67, VHL, MYC | REV1 1520/4885L3MBTL1 2523/4885CHRNA7 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.